E Renard - Diabetes and Metabolism, 2005 - Elsevier Intensive insulin therapy aiming at normoglycemia in order to prevent long-term
complications is not questionable for the management of type 1 diabetes mellitus
nowadays. The gold standard mode of insulin therapy in this view is CSII ... Cited by 17 - Related articles - BL Direct - All 3 versions
M Rachmiel, K Perlman, D Daneman - The Pediatric Clinics of North America, 2005 - Elsevier Type 1 diabetes mellitus (T1D) is a chronic, metabolic disorder that most
commonly presents during childhood and is characterized by absolute insulin
deficiency. T1D is caused by selective immune-mediated autoreactive T-cell ... Cited by 15 - Related articles - All 3 versions
L Guillod, S Comte-Perret, D Monbaron, RC … - Diabetes and Metabolism, 2007 - Elsevier In type 1 diabetic patients (T1DM), nocturnal hypoglycaemias (NH) are a serious
complication of T1DM treatment; self-monitoring of blood glucose (SMBG) is
recommended to detect them. However, the majority of NH remains undetected ... Cited by 14 - Related articles - BL Direct - All 2 versions
- ►canadianmedicaljournal.ca SR Singh, BSP MSc, F Ahmad, A Lal, C Yu, Z … - Canadian Medical Association Journal, 2009 - Can Med Assoc Methods: We updated 2 earlier systematic reviews of the efficacy and safety of
rapid-and long-acting insulin analogues. We searched electronic databases,
conference proceedings and "grey literature" up to April 2007 to identify ... Cited by 13 - Related articles - All 12 versions
H Thisted, SP Johnsen, J Rungby - Basic & Clinical Pharmacology & Toxicology, 2006 - interscience.wiley.com Abstract: For both type 1 and type 2 diabetes, tight glycaemic control is vital
to reduce the risk of long-term complications. However, this must be achieved
with minimal risk of hypoglycaemia. Glargine is a new long-acting insulin ... Cited by 14 - Related articles - BL Direct - All 6 versions
AH Barnett - Vascular Health and Risk Management, 2006 - pubmedcentral.nih.gov Insulin glargine is an analogue of human insulin that is modified to provide a
consistent level of plasma insulin over a long duration. Pharmacokinetic and
pharmacodynamic studies show that a single injection of insulin glargine ... Cited by 4 - Related articles - BL Direct - All 4 versions
SA Brunton - Medscape General Medicine, 2007 - pubmedcentral.nih.gov Nocturnal hypoglycemia may be the most common type of hypoglycemia in
individuals with diabetes using insulin and is particularly worrisome because it
often goes undetected and may lead to unconsciousness and even death in ... Cited by 4 - Related articles - All 4 versions
H Hanaire, V Lassmann-Vague, N Jeandidier, … - Diabetes and Metabolism, 2008 - Elsevier The aim of diabetes treatment is to achieve tight glucose control to avoid the
development of chronic diabetic complications while reducing the frequency of
hypoglycaemic episodes. Continuous subcutaneous insulin infusion (CSII) ... Cited by 3 - Related articles - All 2 versions
M Monami, N Marchionni, E Mannucci - Diabetes, Obesity and Metabolism, 2009 - interscience.wiley.com Aim: Basal insulin in type 1 diabetes can be provided using either NPH (Neutral
Protamine Hagedorn) human insulin or long-acting insulin analogues, which are
supposed to warrant a better metabolic control with reduced hypoglycaemic ... Cited by 2 - Related articles - All 3 versions
S Goykhman, A Drincic, JC Desmangles, M … - Expert Opin. Pharmacother., 2009 - informahealthcare.com Insulin Glargine was the first long-acting insulin analog produced by
recombinant DNA technology, approved for use by the US FDA in April 2000 and by
the European Agency for the Evaluation of Medicinal Products in June, 2000. ... Cited by 2 - Related articles - All 5 versions
